BMC Public Health

Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls: study protocol of a cluster-randomised controlled trial in western Kenya

--Manuscript Draft--

Manuscript Number:	PUBH-D-19-00698R3	
Full Title:	Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls: study protocol of a cluster-randomised controlled trial in western Kenya	
Article Type:	Study protocol	
Section/Category:	Global Health	
Funding Information:	UK-Medical Research Council/Department for International Development/Wellcome Trust/Department of Health and Social Care (MR/N006046/1) Dr. Penelope A. Phillips-Howard	
Abstract:	Background: Adolescent girls in sub-Saharan Africa are disproportionally vulnerable to sexual and reproductive health (SRH) harms. In western Kenya, where unprotected transactional sex is common, young females face higher rates of school dropout, often due to pregnancy, and sexually transmitted infections (STIs), including HIV. Staying in school has shown to protect girls against early marriage, teen pregnancy, and HIV infection. This study evaluates the impact of menstrual cups and cash transfer interventions on a composite of deleterious outcomes (HIV, HSV-2, and school dropout) when given to secondary schoolgirls in western Kenya, with the aim to inform evidence-based policy to improve girls' health, school equity, and life-chances. Methods: Single site, 4-arm, cluster randomised controlled superiority trial. Secondary schools are the unit of randomisation, with schoolgirls as the unit of measurement. Schools will be randomised into one of four intervention arms using a 1:1:1:1 ratio and block randomisation: (1) menstrual cup arm; (2) cash transfer arm, (3) cups and cash combined intervention arm, or (4) control arm. National and county agreement, and school level consent will be obtained prior to recruitment of schools, with parent consent and girls' assent obtained for participant enrolment. Participants will be trained on safe use of interventions, with all arms receiving puberty and hygiene education. Annually, the state of latrines, water availability, water treatment, handwashing units and soap in schools will be measured. The primary endpoint is composite of incident HIV, HSV-2, and all-cause school dropout, after three years follow-up. School dropout will be monitored each term via school registers and confirmed through home visits. HIV and HSV-2 incident infections and risk factors will be measured at baseline, midline and end-line. Intention to treat analysis will be conducted among all enrolled participants. Focus group discussions will provide contextual information on uptake of interventions. Mo	
Corresponding Author:	Garazi Zulaika Liverpool School of Tropical Medicine Liverpool, Liverpool UNITED KINGDOM	
Corresponding Author E-Mail:	garazi.zulaika@lstmed.ac.uk;garaziz53@gmail.com	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	Liverpool School of Tropical Medicine	
Corresponding Author's Secondary		
Institution:		
First Author:	Garazi Zulaika	

Onder of Author	0 :717
Order of Authors:	Garazi Zulaika
	Daniel Kwaro, MD
	Elizabeth Nyothach, MA
	Duolao Wang, PhD
	Emily Zielinski-Gutierrez, PhD
	Linda Mason, PhD
	Alie Eleveld, MPH
	Tao Chen, PhD
	Emily Kerubo, MSc
	Annemieke van Eijk, MD, PhD
	Cheryl Pace, MPharm
	David Obor, MSc
	Jane Juma, MSc
	Boaz Oyaro, MSc
	Louis Niessen, MD, PhD
	Godfrey Bigogo, MSc
	Isaac Ngere, MD
	Carl Henry, BSc
	Maxwell Majiwa, PhD
	Clayton O. Onyango, PhD
	Feiko O. ter Kuile, MD, PhD
	Penelope A. Phillips-Howard, PhD
Order of Authors Secondary Information:	
Response to Reviewers:	16 August 2019
	Dear Editors at BMC Public Health,
	We were so pleased to have our manuscript entitled "Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls: study protocol of a cluster-randomised controlled trial in western Kenya" reviewed by you and your reviewers. We very much appreciate the time and effort put into considering this paper. We have responded to the raised points below and incorporated all changes into our manuscript as described.
	1. Please remove Appendix 1 from the file inventory, as it contains personal information. Please also remove all references to it in the text.
	Thank you for noting this. We have removed Appendix 1 (Full protocol) from the file inventory and have replaced it with Appendix 1 (SPIRIT checklist).
	Reference to Appendix 1 (Full protocol) has been removed from the main body of the text (see lines 105, 424, 490, and 551).
	Reference to Appendix 1 (Spirit checklist) has been added to line 115.
	Please do not hesitate to contact me with any additional feedback or questions.
	Kind Regards,
	Ms. Garazi Zulaika

Garazi.Zulaika@lstmed.ac.uk
Prof. Penelope Phillips-Howard Penelope.Phillips-Howard@lstmed.ac.uk

Click here to view linked References

Cups or Cash for Girls Trial (CCG) v8 16Aug19

- Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in
- adolescent schoolgirls: study protocol of a cluster-randomised controlled trial in western Kenya

Authors

- Garazi Zulaika MPH1 (Garazi.Zulaika@lstmed.ac.uk), Daniel Kwaro MD2 (DKwaro@kemricdc.org),
- Elizabeth Nyothach MA² (ENyothach@kemricdc.org), Duolao Wang PhD¹
- (Duolao.Wang@Istmed.ac.uk), Emily Zielinski-Gutierrez PhD3 (ebz0@cdc.gov), Linda Mason PhD1
- (Linda.Mason@Istmed.ac.uk), Alie Eleveld MPH5 (alie@swapkenya.org), Tao Chen PhD1
- (Tao.Chen@lstmed.ac.uk), Emily Kerubo MSc2 (EKerubo@kemricdc.org), Annemieke van Eijk MD
- PhD¹ (Anna.vanEijk@lstmed.ac.uk), Cheryl Pace MPharm¹ (cherylp111@gmail.com), David Obor
- MSc² (DObor@kemricdc.org), Jane Juma MSc² (JJuma@kemricdc.org), Boaz Oyaro MSc²
- (boyaro@kemricdc.org), Louis Niessen MD PhD1 (Louis.Niessen@lstmed.ac.uk), Godfrey Bigogo MSc2
- (GBigogo@kemricdc.org), Isaac Ngere MD⁶ (ngereisaac@gmail.com), Carl Henry BSc¹
- (Carl.Henry@lstmed.ac.uk), Maxwell Majiwa PhD² (mmajiwa@kemricdc.org), Clayton O. Onyango
- PhD⁴ (xwl4@cdc.gov), Feiko O. ter Kuile MD PhD¹ (Feiko.Terkuile@lstmed.ac.uk), Penelope A.
- Phillips-Howard, PhD^{1*} (Penelope.Phillips-howard@lstmed.ac.uk).
 - 1. Department of Clinical Sciences, Liverpool School of Tropical Medicine (LSTM), Liverpool, UK.
- 2. Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu,
- Kenya.
 - 3. Center for Global Health, Division of Global Health HIV and TB, U.S. Centers for Disease
- Control and Prevention (CDC), Nairobi, Kenya.
 - 4. Center for Global Health, Division of Global Health Protection, U.S. Centers for Disease
- Control and Prevention (CDC), Nairobi, Kenya
- 5. Safe Water and AIDS Project (SWAP), Kisumu, Kenya.

6. Ministry of Health, Siaya County, Kenya.

*Corresponding author: Prof. Penelope Phillips-Howard, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, United Kingdom. Tel: +254702 126188. Fax: +447985431005. E-mail: Penelope.Phillips-Howard@lstmed.ac.uk.

Abstract

Background: Adolescent girls in sub-Saharan Africa are disproportionally vulnerable to sexual and reproductive health (SRH) harms. In western Kenya, where unprotected transactional sex is common, young females face higher rates of school dropout, often due to pregnancy, and sexually transmitted infections (STIs), including HIV. Staying in school has shown to protect girls against early marriage, teen pregnancy, and HIV infection. This study evaluates the impact of menstrual cups and cash transfer interventions on a composite of deleterious outcomes (HIV, HSV-2, and school dropout) when given to secondary schoolgirls in western Kenya, with the aim to inform evidence-based policy to improve girls' health, school equity, and life-chances.

Methods: Single site, 4-arm, cluster randomised controlled superiority trial. Secondary schools are the unit of randomisation, with schoolgirls as the unit of measurement. Schools will be randomised into one of four intervention arms using a 1:1:1:1 ratio and block randomisation: (1) menstrual cup arm; (2) cash transfer arm, (3) cups and cash combined intervention arm, or (4) control arm.

National and county agreement, and school level consent will be obtained prior to recruitment of schools, with parent consent and girls' assent obtained for participant enrolment. Participants will be trained on safe use of interventions, with all arms receiving puberty and hygiene education.

Annually, the state of latrines, water availability, water treatment, handwashing units and soap in schools will be measured. The primary endpoint is composite of incident HIV, HSV-2, and all-cause school dropout, after three years follow-up. School dropout will be monitored each term via school registers and confirmed through home visits. HIV and HSV-2 incident infections and risk factors will

- be measured at baseline, mid-line and end-line. Intention to treat analysis will be conducted among all enrolled participants. Focus group discussions will provide contextual information on uptake of interventions. Monitoring for safety will occur throughout.
- **Discussion:** If proved safe and effective, the interventions offer a potential contribution toward girls' schooling, health, and equity in low- and middle-income countries.
- Trial registration: ClinicalTrials.gov NCT03051789, 15th February 2017
- Keywords: Sexual and reproductive health; adolescence; equity; HIV; HSV-2; pregnancy; school
 dropout, clinical trial, menstruation, Kenya, study protocol.

Background

Young persons aged 10-24 years (yr) make up a quarter of the worlds' population, contributing 1.8 billion persons of whom approximately 90% live in low or middle-income countries (LMIC). Adolescence is a critical time of psychological and biological change, and advocacy has increased to identify interventions that protect young peoples' lives (1). These interventions include ways to protect against sexual and reproductive health (SRH) harms, which are disproportionately high among adolescent girls in sub-Saharan Africa (SSA) (2, 3). Each year an estimated 14 million girls aged 15-19yr give birth (2). Maternal causes kill more girls in this age group than any other cause (2). Thus, delaying pregnancy to adulthood is important for women's reproductive health and infants survival as well as their economic and social empowerment (4). In much of east and southern Africa including western Kenya, where unprotected transactional sex is common, young females are highly vulnerable to sexually transmitted infections (STIs), including HIV which may result in mother-to-child transmission (2, 3). The burden of young female SRH harms is high for individuals, and on their communities and health services, yet sustainable preventive interventions are lacking. Evidence of a positive association between girls' education, and their health and economic potential, has strengthened international resolve to improve educational opportunities for adolescent girls. While SRH education has not been

demonstrated to have a large impact on SRH harms (5), staying in school has shown to protect girls against early marriage, teen pregnancy, and HIV infection, with schoolgirls reporting less frequent sex, and fewer partners with less age disparity (6-8). Building on the Millennium Development Goals (MDG), which focused on primary school attendance, the post-2015 Sustainable Development Goals encourage investment in secondary, tertiary and vocational education to build human capital, encourage innovation and spur economic growth (9).

Intervention studies using cash transfer (CT) have demonstrated a protective effect on girls SRH (including HIV, HSV-2) and school indicators (8, 10, 11), although results in other studies have been inconclusive (12, 13). Dropout before secondary school completion is partly explained by girls' vulnerability once they engage in premarital sex, which is often a precursor to unintended pregnancy or early marriage (7, 14, 15). Studies have illustrated adolescent girls' vulnerability to transactional or coercive sex, to obtain necessities such as soap, sanitary products, and underwear (16-19). Products for menstrual hygiene management (MHM) are one such necessity, and their accessibility remains a pervasive problem in LMIC. A lack of MHM materials, awareness, and facilities, as well as stigma, negatively impact girls' school-life (20, 21), and can be a driver of girls' vulnerability to coercive sex. In western Kenya, 10% of 15yr old girls self-reported they obtained money through sex to purchase sanitary products (22). To better understand girls MHM needs in western Kenya, a pilot study in rural primary schools was conducted measuring girls' menstrual practices, uptake, and safety of a reusable menstrual cup (MS Pilot Study) (23, 24). The pilot results demonstrated acceptability of the menstrual cup (25), with a lower prevalence of STI and bacterial vaginosis found at 9 and 12 month follow-up among girls using the cup when compared to controls (26), and good clinical safety (16). Prevalence of school dropout after 12 months was lower but inconclusive due to the small sample (26).

To verify the results of the MS Pilot Study and examine the efficacy, safety, and cost-effectiveness of different school-based interventions in improving girls' SRH, schooling, and life-chances in rural western Kenya, a randomized controlled trial was designed with a larger population and follow-up duration. The study is designed to inform evidence-based policy to improve girls' health, school equity and their life-chances which is summarised in this article.

Methods

, 108 Design Overview

This study is a single site, open-label, 4-arm, school-cluster randomised controlled superiority trial taking place in Siaya County, western Kenya. Schools are the unit of randomisation (clusters), with girls as the unit of measurement. Schools will be randomly allocated into 4 arms using a 1:1:1:1 ratio and block randomisation to minimise bias. Enrolment will open in the first school term of 2017 after trial registration and continue until we reach the necessary sample. Girls will be followed-up through graduation and into employment or up to 10 academic terms to determine if they complete secondary school (Form 4), see Appendix 1: Spirit Checklist.

Primary objective

To determine the impact of menstrual cups or CT alone, or in combination, on a composite of deleterious outcomes (HIV, HSV-2, and school dropout) when given to secondary schoolgirls in western Kenya.

Secondary objectives

 To measure the age-specific differences in the acquisition of HIV and HSV-2 infections in secondary schoolgirls and risk factors for incident HIV and HSV-2 infections.

- To determine the risk, risk factors and reasons for dropout and other school indicators among 2. secondary schoolgirls examining the influence of social, epidemiological, and/or health characteristics.
 - To determine the cost benefit of menstrual cup and CT programmes for schoolgirls by assessing the cost savings of outcomes averted, for individual and combined interventions, and resulting societal impact.
- To determine the safety of menstrual cup use, including risk of cup contamination over time, serious adverse events, and identify factors that increase or modify this risk.
- To determine factors affecting how adolescent girls spend CT money, and what training is required to support their financial literacy and decision-making.
- To determine any adverse outcomes associated with CT and evaluate ways to mitigate risk.
- 7. To determine the impact of the interventions on girls' sexual behaviours, including age of sexual début, coerced sex, number of partners, age of partners, pregnancy, condom use and use of contraception.
 - To examine programme implementation for interventions in schools, working with beneficiaries and stakeholders to develop programme implementation packages.

Design Considerations

Why secondary schoolgirls?

Among schools located in our proposed study area, the dropout rates are higher among girls in secondary when compared to primary school girls. Unpublished school enrolment data for 2015 in the study location shows that only 26% of primary school girls drop out of primary school compared to 36% who drop out of secondary school (local school enrolment data, unpublished). These high dropout rates for secondary schoolgirls exert a high burden on the national economy, with lifetime cost of dropout estimated to be 48% of GDP (4). Our pilot study found that following the abolition of primary school fees 6 years ago, girls complete primary at a younger age (<15yr). Thus, fewer girls in

 primary school reach menarche and sexual debut. While prevalence of HIV was low in our primary school cohort (<1%), health studies in the same study area have documented very high HIV incidence for secondary school-aged girls, who range in age from 13-30. In one study, HIV prevalence was 8.8% in 15-19yr olds, sharply rising from 1.3% among 13-14yr olds to 3.3% in 16yr olds and 12.8% in 18yr olds (27). A similar steep increase by age was seen in HSV-2 prevalence (27). A high prevalence of STIs was detected in 15-19yr old girls in neighbouring Kisumu (28). In pilot study focus group discussions (FGDs), when asked about reasons for drop out, girls voiced reasons linked to exposure to sexual activity (resulting from alcohol, funeral parties, needs for money, and coercive sex), and these were more frequently stated among older girls (17). During these FGDs, girls were able to vocalise their concerns about pregnancy risks, and issues around lack of money for school and personal needs. They reported that their menstrual needs were unmet but a high priority and at times compelled them to have sex to obtain money to buy pads (17). In a separate study in the same area, 10% of 15yr olds surveyed reported they had sex for money in order to purchase sanitary pads (22).

Justification for a composite endpoint

The primary composite endpoint will include incident HIV, HSV-2, and school dropout in girls seronegative or for both HIV and HSV-2 on enrolment or undetermined sero-status at enrolment (conservatively the sample size allows for 20% refusal for testing at baseline). The presence of HIV or HSV-2 at enrolment precludes the components from contributing to the primary composite endpoint. Thus, among HIV-negative girls who were HSV-2 positive on enrolment only incident HIV infection and school dropout would contribute to the primary endpoint; among girls who are both HIV and HSV-2 positive on enrolment, only school dropout would contribute. This endpoint represents the key drivers compromising girls' health and life chances into adulthood. The rationale behind this composite endpoint is to increase the power for a given sample and to build a single outcome across all girls regardless of their independent HIV and/or HSV-2 status at enrolment.

Justification for cumulative school dropout

The cumulative risk of school dropout among secondary schoolgirls is an acute problem in western Kenya; 36% of girls drop out before the start of the fourth and final year of secondary school due to teen-age pregnancy, lack of school funds, illness, work or family commitments, or viewing school as unnecessary (17). The need for MHM is also perceived as a constant stressor impacting school-life given that traditional MHM items (rags, paper, etc) leak, cause odour and discomfort, and cause girls to habitually miss school and fall behind. Some evidence suggests that poor MHM even leads some to engage in transactional sex for essential 'luxuries' such as pads and soap (17, 22). During the pilot study (23-25), we found that use of MHM products (reusable menstrual cups or pads) for at least 1 year had the potential to prevent school dropout (26). CT programs also have shown potential for CT improving the odds of being enrolled in and attending school, improving household socio-economic status (SES) and quality of life, and reducing early marriage (29, 30). In the trial, we define dropout as not attending school consecutively for at least 1 term or longer. Girls who attended part or all of Form (class) 4, but then do not sit the final national Kenya Secondary Certificate of Education (KSCE) exams will be considered a dropout in that final term. Other secondary school indicators such as grade repetition will also be documented. Girls who return to school after being classified as a dropout will be classified as re-enrolled.

Justification for cumulative risk of incident HIV and HSV-2

Risky sexual exposure can cause harm to a girl's sexual and reproductive health and negatively affect her life-chances even while remaining in school. The pilot showed high prevalence of laboratory confirmed STIs in this rural area in western Kenya even among primary schoolgirls (28% of girls had reproductive tract infections, predominantly bacterial vaginosis) (26, 31). Community surveys in the pilot site found an HIV prevalence of 11% among females under 30yr, rising from 1% in 15yr to 20% by age 29 (22, 27), and a reported 52% of girls in this area engaging in transactional sex for money,

gifts or services (32). HSV-2 is the most common cause of genital ulcer disease worldwide, the most prevalent STI in sub-Saharan Africa, and a well-established biomarker for sexual risk behaviour (8, 33, 34). Evidence suggests HSV-2 prevalence in girls in the study area increases from 10% in 13-14yr to 28% in 15-19yr, and 70% among the 20-24yr (27, 35).

A trial in Malawi that provided CT to school girls aged 13-22yr found that HIV and HSV-2 prevalence were 33% and 70% lower respectively in CT recipients after 18m intervention when compared to controls (8). Results were supported with reduced frequencies of self-reported sexual activity and less age discordant sex (8). The impact of menstrual cups on HIV or HSV-2 has not been evaluated, but when assessed during the pilot study, cups were associated with a lower prevalence of STIs and bacterial vaginosis (26), both important risk factors for HIV acquisition and transmission (36-38). This information corroborates reported narratives that control-arm girls most acutely felt the need to have sex to obtain sanitary pads (24, 25). Laboratory confirmation of infections is essential, however, as girls and young women's reported symptoms are poorly predictive of infection (31, 39-43).

Study setting

The study will be conducted in in schools in Siaya County in rural western Kenya, extending to contiguous areas that include Kisumu County if needed. The site is in a health and demographic surveillance system (HDSS) positioned 400 km west of Nairobi, with its southernmost point reaching Lake Victoria (44). The population are mostly members of the Luo ethnic group, and are mainly subsistence farmers (45). Siaya is an impoverished area, with previous studies estimating households have a mean annual income approximating \$600 to \$700 (46). An estimated four out of ten child learners miss school daily in Siaya County (47). Gender equity seen in primary school falls during adolescence, with between 25%-33% more boys than girls attending secondary school by age 18 (48, 49). The disease burden typifies rural African communities (44), with mortality in adolescents and young adults attributed to communicable diseases, injuries (50), and maternal causes (51). Advances

 in antiretroviral therapy (ART) access have been associated with reducing adolescent and young female mortality by half (50, 52). Physical and sexual violence against females is one of the highest in Kenya, with 12% of women reporting their first sexual intercourse was coerced (53), rising up to 45% among adolescent girls (54). The former pilot study evaluating menstrual interventions was conducted in one of the three sub-divisions within the study area, with water, sanitation, and hygiene (WASH) observations illustrating presence of latrines and water, but not soap in schools (23). The menstrual care among the population was examined and illustrate girls' and young women's preference for commercial pads over traditional items; with 10% of 15yr olds reporting they had sex for money to purchase sanitary pads (22). Schools and health facilities have been geolocated (see Figure 1, below).

Figure 1 – Map of Siaya County Public Health Facilities and 96 CCG Study Schools

Eligibility criteria: schools

- Inclusion criteria for schools
- Secondary school within study area
- Girls or co-educational school
- Day school
- Approval by Head Teacher

249 Exclusion criteria for schools

- 50 250 Boys only school
 - Boarding schools
 - Special needs schools (i.e. for the blind)

Eligibility criteria: participants

- 255 Inclusion criteria for participants
- Attend secondary day schools in the study area
- Resident of the study area
- Have a history of established menses (>=3 times)
- Have no disability preventing participation
- Assent to participating in the study and have received parent or guardian consent
- 261 Exclusion criteria for participants
- Attend boarding schools
- Visibly pregnant or declare pregnancy at baseline (girls who don't declare pregnancy but whose
- delivery dates confirm pregnancy started prior to enrolment will be excluded from the analysis.)

266 Trial interventions

- 267 Schools will be randomised to one of 4 arms:
- 268 1. One menstrual cup with training on safe use and care, with handwash soap termly.
- 269 2. Cash transfer (CT) Ksh 1500/term plus financial literacy training.
- 3. Combined menstrual cup and CT with training on financial literacy and cup safe use and care.
- 4. 'Usual practice' control (control arm), with handwash soap termly.
- 272 All participants regardless of school cluster will receive puberty and hygiene education.

274 Menstrual cup

The menstrual cup is a medical grade silicone bell shaped container which is inserted into the vagina
to collect menstrual flow, and requires emptying at regular intervals (4-8 hours) (55). Cleaning by

boiling is recommended at the end of each cycle. The Mooncup® will be used in the t/rial (56), selected

because it has been tested in the UK (57, 58) and internationally (26, 59), is produced to ISO

13485:2003 standards, and registered by the U.S. Food and Drug Agency of Medicines (FDA;

280 Registration Number 3009117944); and was successfully used in the pilot study (54). Further, its' white

colour when new, changing to brown after use, allows physical observation of use (26). Girls will receive school-based training on safe cup use and care (including insertion, emptying, re-insertion, cleansing, and storage). The trial will document girls' use over time.

Cash transfer pocket money

Cash transfer (CT) programmes are a popular social protection tool in developing countries that aim, among other things, to improve education outcomes and reduce risky sexual behaviour (8, 10, 11, 60, 61). A sum of US\$5 per month (~Ksh500; exchange December 2015) was recommended for future studies. CT programmes which were conditional on attendance have been shown to improve school outcomes more than unconditional or non-monitored (29). This trial will provide Ksh1500 (US\$15) per term (3 terms per school year) for up to 10 academic terms. Conditionality for CT receipt will be based on 80% or more school attendance in the previous term, in line with other studies (8, 61-64). After assent, participants in the CT arms will receive school-based financial literacy training and a bank card. For this trial, Equity Bank pre-paid cash cards will be used for minors after obtaining guardian consent. Girls must provide a birth certificate and a guardian ID to receive a bank card. Precautions will be taken to ensure girls have direct access to their accounts but maintain low visibility to minimize the risk of theft, harassment, or violence. School registries will be assessed retrospectively per term to verify school attendance, with spot-checks conducted to minimise risk of falsification of registries. The trial will document girls' use and spending choices over time.

Endpoints / Outcome measures

- *Primary outcome:*
- 303 Composite: incident HIV, HSV-2, all-cause school dropout by the end of the study.

Secondary outcomes:

School dropout

HSV-2 incidence

- HIV incidence
- Reported sexual behaviour indicators (including age at sexual debut, age-discordance of partners,
- coercive sex, number of sexual partners, pregnancy, condom use, and use of modern
- contraceptives)
- School performance indicators (Kenya Certificate of Secondary Education [KCSE] results, grade
- repetition, prevalence of re-enrolment, and absenteeism)
 - Quality of life using EuroQoL and PEDSQL
 - Cost-effectiveness of interventions from the societal, including girls', perspective
- - Safety endpoints
 - Tolerability: any adverse events assessed in a general reproductive health questionnaire
 - Primary Safety:
 - Toxic Shock Syndrome
 - Violence associated with interventions provided
 - Secondary Safety:
 - E. coli growth on sampled cups
 - Other emergent harms that may occur with provision of cash pocket money or cups.

Sample Size estimates

minimum number of schoolgirls needed in the proposed 4-arm trial using sample size calculation software (NCSS/PASS); calculations were validated using SAS based simulation studies. Five primary comparisons of the primary endpoint were tested: (1) menstrual cup vs usual practice, (2) CT vs usual practice, (3) combined CT and cup vs usual practice, (4) combined CT and cup vs menstrual cup only,

Original trial design sample size estimate: Sample size and power calculations were performed for the

and (5) combined CT and cup vs CT only. Calculations were based on a 2-sided alpha of 0.01 to allow

5 primary comparisons of interest, assuming an ICC value of 0.008. Taking a target of mid-late Form-1 of schools in the study area gives a sample size average of 46 girls, a 1yr enrolment period, a 5% overall refusal to take part in the study, 20% refusal at enrolment to consent to HIV testing among participating girls, an average of 10 terms (~3.3yr) follow-up through the end of Form-4, and 20% loss to follow-up or refusal to provide biological samples at the end of the study period. Of 46 enrolled girls/school, on average, 35 (0.95*0.80x46) will contribute to the primary analysis; we assume that 6.9 will be HSV-2 or HIV positive on enrolment (24.7% of 28 girls who agree to testing) and the remaining 28.1 will be HSV-2/HIV negative (n=21.1) or of unknown HSV-2/HIV sero-status (n=7) because no assent/consent was provided for testing at enrolment. With these assumptions, a trial with 4 arms of 21 schools per arm (84 schools total) enrolling 46 girls/school (i.e. 966/arm; 3864 girls total) with 35 girls/school contributing to analysis, will have 90% power to detect a 25% reduction (Relative Risk [RR]=0.75) in the 3.3yr incidence risk of the primary endpoint from 44.1% in the control group to 33.1% with either intervention, and 80% power to detect a 22.2% reduction (RR=0.778) to 34.3% (both at alpha=0.01).

Source data: The ICC value of 0.008 was the observed ICC value for the composite endpoint of school dropout and STIs in our previous pilot study, and 0.0084 for school dropout alone (26). The anticipated effect sizes of 25% (RR=0.75) for the primary endpoint is based on a model combining the impact and event frequency of the 3 components of the primary endpoint in the three strata: HSV2/HIV negative girls (60.2% of the overall sample), HSV-2 or HIV positive girls (19.8% of the sample), and girls for whom the sero-status is unknown (20% of the sample). The model predicts that a 25% (RR=0.75) overall reduction from 44.1% to 33.1% with single interventions, or from 33.1% to 24.8% with the dual intervention can be achieved with the following combination of relative risk reductions for school dropout and HIV and HSV-2 incidence respectively: 30% and 25.7%; 25% and 34.2%; or 20% and 43.0%. The anticipated minimum reduction of 30% in dropout is based on an average 31% reduction in a meta-analysis comparing controls against cash transfer (29), and is more conservative than a 58%

reduction observed with menstrual cups in year-2 of the pilot (26). The 48.8% reduction in HIV and HSV-2 incidence is based on a 51.9% reduction observed in year-2 of the pilot study, adjusted for the fact that baseline HSV2-HIV status would not be available for 12 of 60 girls/school (20%) on enrolment, 3 to 4 of whom may have undetected HSV-2 or HIV on enrolment. The observed relative risk reduction in the HIV and HSV-2 <u>incidence</u> was 48.8% (based on a 43.4% reduction in STI <u>prevalence</u> by the end of the previous pilot in 2014) (26).

(2) Blinded sample size re-estimation

A blinded sample size re-estimation was conducted in 2017 using the baseline data from all arms pooled to validate the assumptions made during the original sample size estimations in the trial design phase. The average number of girls per school and the baseline prevalence of HSV-2/HIV (a proxy for the anticipated incidence) were lower than anticipated. A sample size re-estimation with pooled data demonstrated that a total of 96 school clusters (24/arm) are required with an anticipated average of 41.25 girls per cluster to obtain 90% power to detect a 25% (RR=0.75) reduction in the primary endpoint from 39.3% in the control arm to 29.5% in any of the 3 intervention arms (alpha=0.0167 allowing for 3 primary comparisons against the control arm), with an ICC of 0.008 and allowing for 20% loss to follow-up. This yields a full sample of 3,960 overall, 3,168 of whom are expected to contribute to the primary endpoint, 33 per cluster. This same sample size provide 80% power to detect a 25.7% (RR=0.743) reduction from 29.5% in any of the single intervention arms to 21.9% in the combined intervention arm (alpha=0.025). The total sample size may exceed 3,960 if the average cluster enrolled has more eligible girls than anticipated as the intention is to give every eligible girl in each secondary school the opportunity to participate.

Assignment of interventions

Allocation

School clusters are the unit of randomisation and girls the unit of measurement. A census of secondary schools in the area will be used to select the eligible schools. The trial statistician will produce block randomized groupings of four schools (blocks) using a 1:1:1:1 ratio and based on location and size, including larger schools (e.g. with more than 20 target girls) for logistical reasons. Arm allocation of schools to intervention arms will be achieved using community ceremonies. During a public ceremony, head teachers representing their respective school will be called up with the rest of their blocks for balanced randomization. The head teachers will each simultaneously pick 1 of 4 coded items, and once all blocks have completed this process and all schools have been randomly allocated, study arm will be displayed by opening sealed envelopes and breaking the code. This methodology was informed by the pilot study where randomisation ceremonies with head teachers were successful (26).

Blinding

Participants cannot be masked to their treatment arm due to the nature of interventions provided. Laboratory personnel testing for HIV and HSV-2, investigators, and trial statisticians will be blinded to the study arm. Field staff will be masked as much as feasible, including those who conduct home visits to confirm dropout. Bias will also be minimised by use of block randomisation stratified by school size. An independent person will prepare the sealed envelopes with the study arm allocation. Study arm allocation will not be recorded in the central database to ensure the trial statistician and data managers remain blinded throughout the study. This information will be recorded separately and only be merged with the main database following approval of the statistical analysis plan (SAP), closure of the databases and submission of a copy to the independent statistician of the Data Monitoring and Ethics Committee (DMEC).

Participants' timeline

Overview

The participant's timeline will commence after pre-recruitment preparations, including ministry, school, and community stakeholder meetings and approvals. Parent consent for their daughters' participation will follow the school cluster randomisation ceremonies. Participants' meetings for assent, pre-screen enrolment and baseline screening, mid-line screening (second study year), and end-line screening (third study year) will be held as 'Health Days' in randomised schools.

Figure 2-Flowchart of Randomization and Study Design

Pre-screen Enrolment, Assent and Baseline Screening

The school enrolment register will be used as the sampling frame to define all target girls in the study schools. Parents of all girls will be approached at the end of the school information meeting to request informed consent for (1) the main study, (2) HIV testing and counselling, and (3) blood storage. Signing will be private and one-to-one with a trained member of the study team. The enrolment list will be updated at the meeting to record girls transferring out or into the school and missed parents will be followed up at home for consent. Reasons for non-consent will be documented.

Girls whose parents have consented to their participation in the study will be informed of the study purpose and procedures. Each girl will individually be asked to give her assent to participate and asked key eligibility criteria questions (see eligibility criteria: participants, above). Girls who meet the eligibility criteria will then be invited to participate in the study.

Participants will privately self-administer a combined demographic, social, behavioural and quality of life/wellbeing questionnaire using tablets during the 'Health Day'; absent girls will be invited to participate at a subsequent 'Health Day' when logistically feasible. All relevant information will be captured in the survey questionnaire. Baseline questions around demographics, use of menstrual

items, and access to cash and personal bank account will be asked, as well as other secondary outcomes. Wellbeing will be assessed using the adolescent (12-18yr) 23-item PedsQLTM 4.0 (Paediatric Quality of Life Inventory; http://www.pedsql.org/), and will measure physical, emotional, social, and school functioning of children, core dimensions as delineated by WHO (65).

A baseline clinical survey will be conducted to define pre-intervention HIV and HSV-2 prevalence, and height, weight, and waist measures of participants. Documentation of population HIV prevalence is important to understand frequency of mother-to-child transmission of HIV, noted in a Zimbabwean schoolgirl CT study which only evaluated HIV and HSV-2 at endline (30). However, refusal to have an HIV or HSV-2 test at baseline will not preclude participants from joining the study. School 'Health Days' will be operated with a trained mobile team at a location at or close to their school. All sample collection and HIV counselling will be conducted by a team of trained HIV Testing and Counselling (HTC) staff. Results will not be given then, but separately to participants on an individual level at the health clinics with trained counsellors and testing and counselling and care facilities. Participants can visit clinics individually without peer pressure and are encouraged but not obligated to ask their parents to accompany them. If consent/assent has been obtained for blood collection, girls will provide 600uL of blood for HIV and 1.5ml for HSV-2 with any blood not used for these two tests stored as dried blood spots for future testing of other STIs or vaccine preventable infections, if funding allows. Blood will be collected through fingerpick and stored and transported in Microtainer EDTA tubes to KEMRI laboratories for analysis. Blood will be stored for a maximum of 5yr, after completion of the trial, after which it will be destroyed.

Midline screening

All participants will be invited to participate in a mid-study behavioural survey to update sociobehavioural characteristics, including marriage status, sexual exposures, and document patterns of intervention use, problems encountered, and any possible safety issues. Midline HIV/HSV-2 testing

will be conducted mid-study. These tests and follow-up counselling and treatment will follow the same methodologies used at baseline. These measurements will allow closer examination of incidence over time and offer the opportunity to test and counsel participants who exit the study before the endline survey. Baseline consents and assents include this assessment. Participants are reminded they have the freedom to withdraw or refuse testing.

End study screening

Similar to the baseline Health Day, participants will attend an end of study Health Day to complete an endline behavioural survey to document changes in socio-behavioural characteristics (including risky sexual behaviours, quality of life/wellbeing measures) and intervention use, problems encountered, and any perceived harms. Outreach activities to survey enrolled girls who have left school or dropped out will be conducted if funding is available. HIV and HSV-2 serostatus will be assessed at this same Health Day to determine incidence among those testing negative at enrolment and during interim follow-up testing. Careful consideration and coordination with head teachers will be needed to secure the dates for the final survey to ensure no disruption for girls in Form 4 while they take final exams. Endline HIV/HSV-2 testing will be conducted on Health Days in safe spaces among all enrolled girls to protect the confidentiality of baseline HIV positive participants.

Participants are reminded they have the freedom to withdraw or refuse testing.

Unscheduled visits

School dropout will be assessed every term until the study end. Regular monitoring of school registers will be conducted to determine dropout among participating girls. Girls who dropout will be followed-up with an unscheduled visit to the home to understand reasons for dropout and confirmation of the same, and to identify those that have migrated to a different area who may still attend school (e.g. are classified as loss to follow-up). An unannounced annual WASH survey will be conducted at all participating schools, to observe the presence and state of latrines, water

interventions, use, impact and any problems arising.

availability, water treatment, handwashing units and soap. At any time, participants displaying adverse events will be assessed by a study nurse, with a triage form evaluating seriousness and potential relationship with the interventions and tailored AE and SAE forms to document relevant details (see Appendix 2: SAE Report Form).

Focus group discussions

FGDs will be held pre-intervention, annually (interim) during the trial, and at the end of the study. Feedback from these will document participant and other beneficiaries understanding of the

Laboratory Procedures

Clinical testing

HIV testing will be conducted in accordance to Kenyan national guidelines (66). HSV-2 will be examined using Kalon gG2 ELISA test kits (Kalon Biologicals Ltd, Guilford, UK), with quality assurance performed. Any additional blood collected at baseline, interim, or end of study will be stored for future testing of other STIs or vaccine preventable infections, if funding allows.

Cup contamination

A register of all participants receiving cups will be used to randomly select a swatch of used cups by duration of provision. This will exclude girls who received a replacement cup due to loss, theft, or damage. Randomly selected participants will be traced and asked if they are willing to swap their existing cup for a new one, to allow laboratory examination of their cup. Each used cup will be placed in a separate lock- bag labelled with participant ID and transported to the laboratory and tested for E coli growth. Cups will be swabbed using polyester tipped swabs moistened in normal saline and inoculated into both MacConkey (MAC) agar and blood agar (BA) and incubated for 18-24 h at 37°C. After incubation, colony types will be visualized for characteristic morphology of E.coli and others from the MAC plates, and subjected first to analytical profile index (API) testing for suspected E coli growth(67), then incubated for 18-24 h at 37°C. The results will be interpreted using API software(68).

Statistical methods

- A study statistical analysis plan will be developed during the course of the study for the final analysis.
- This will be completed prior to the unblinding of data at database lock.

Screening failures

A participant who gives informed assent (after parental consent) and is provided with a study ID, but then is found not to fulfil the eligibility criteria, will be classified as a screening failure and excluded from the intention-to-treat (ITT) and the per protocol (PP) analysis. Pregnant girls who do not declare pregnancy at enrolment will be excluded from analysis after the dates of normal (or otherwise) deliveries confirm that the current pregnancy was ongoing at enrolment.

Intention-to-treat (ITT) population

provided parental consent, themselves assented, and were enrolled into the study. These girls will be

included in the intention-to-treat analysis regardless of whether they have completed all endline

The intention-to-treat population (the full analysis population) is defined as all participants who

evaluations.

Per protocol (PP) population

 The per-protocol population within the menstrual cup groups is defined as all participants receiving

the cup with evidence it changed colour showing actual use. For cash transfer, 'per protocol'

constitutes all girls receiving the cash intervention until dropout or reaching the endpoint.

Participants documented to have crossed over between school clusters will be excluded.

14 545

26 550

561

Discussion

Cost-effectiveness analyses

An economic evaluation will be conducted to provide evidence for the cost-effectiveness of the three interventions. This will be used to estimate the societal cost consequences and efficiencies of the intervention packages to inform health service delivery and future policy decisions.

Safety outcomes

Adverse events (AEs) and serious adverse events (SAEs) will be monitored, managed and recorded during the study (see Appendix 2: SAE Report Form). AEs will be reported and tabulated for each treatment arm, overall, and according to body system on a per protocol basis. Intervention emergent AEs are defined as adverse events that had an onset on the day of the intervention, or thereafter. AEs that have missing onset dates will be considered to be treatment emergent. No formal statistical testing will be undertaken. All laboratory data will be listed and summarised.

Ethics approval and consent to participate

This protocol, the informed parent consent and participant assent documents, and participant information sheets have been reviewed and approved by the Research Ethics Committees at the Kenya Medical Research Institute, Nairobi, Kenya (KEMRI protocol #3215) and the Liverpool School of Tropical Medicine, Liverpool (LSTM protocol #15-005). The Centers for Disease Control and Prevention gave approval for reliance on the KEMRI IRB (2016-136). Registry approval for trailing menstrual cups was given by the Kenyan Poisons and Pharmacy Board (ECT_16_07_06). Annual renewal of approvals by KEMRI, LSTM, and KPPB are required based on reporting of trial activities in the prior year.

 In this study we are hypothesizing that, as a result of receiving the trial interventions, participating adolescent girls' health and schooling will improve. Prior studies have illustrated that the provision of a menstrual cup can lower rates of reproductive tract and sexually transmitted infections (26); and that the provision of cash transfer impacts positively on girls' schooling outcomes (8, 13). Moreover, evidence is building that enrolment and consistent attendance in school acts as a social vaccine with multiple benefits for girls(6, 15). This trial will determine if provision of a menstrual solution alone, or in combination with cash transfer directly to schoolgirls can improve their life chances, in terms of reducing their risk of HIV, STI (HSV-2), and school dropout. In our trial, we postulate the interventions tested (cups alone, CT alone, or cups and CT) will lead to a reduction in schoolgirls' exposure to sexual and reproductive harms, while increasing their opportunity to complete their schooling, compared with controls. Enrolment, intervention and follow-up of participants across a wide geographical area in rural Africa requires a strong collaboration with schools, communities and organisations. The collaboration in western Kenya between KEMRI, LSTM, SWAP, CDC and government of Kenya (GoK) provides this. Parallel small group sessions evaluating programme fidelity and uptake will inform and strengthen the development of programmatic materials for implementation, should the trial show positive outcomes. Our research will be communicated to the UK and Kenyan public, Kenyan local, county and national ministries, NGO and aid agencies, national and international universities, research groups, international development and aid agencies, donor organizations, and international agencies setting

global policy. We will use multiple communication strategies to target information to the correct audience, as appropriate. Much will be through face-to-face interactions at workshops, meetings, local forum presentations, and international conferences. Communication through technology transfer will be used to disseminate more widely to a broader audience, through online networks, webinars, online news, blogs, and publication portals.

We hope that if the interventions prove to be successful and our communication strategy sound, this trial could contribute to improved retention of adolescent girls in school, and could have multiple benefits for health and education services, and national and global level development. This growing evidence base must be used to help girls complete their educations and become financially independent adults, better manage their own menstrual hygiene, and reduce the negative psychosocial pressures and stigma leading to sexual exploitation, violence, illness, premature marriage, and death during childbirth. Cascading benefits may include that communities will benefit from an increase in social capital, and a reduction in resources required to support unemployed, sick, and pregnant girls. Evidence-based-policy will lead to schools being beneficiaries, by improving girls' experience of menstrual care in school; and teachers will benefit from girls' improved attention in class and equitable teaching. As more girls complete education, there will be greater opportunity for training female teachers, redressing the gender imbalance. More engaged pupils will increase teachers' job satisfaction and better grades will raise school profiles. Partnerships between education and the health sector will be strengthened. Economic benefits would translate nationally; for example, researchers estimate that in Kenya, if all 1.6m adolescent girls were able to complete secondary school, and the ~220,000 girls who were pregnant and delivered could be educated, there would be a cumulative effect adding up to £2.1 billion towards Kenya's gross income per year (4). Implementation of successful interventions globally will increase the number of girls completing school, reducing the current global estimate of 44m adolescent girls out of school. Implementing interventions that retain girls through secondary school will have global economic benefits, as it is estimated that countries growth rates would increase on average by ~1% annually if girls' education was raised one level higher (i.e. secondary status). Interventions will reduce the prevalence of teen births and poor maternal outcomes, and the rate of new HIV infections in adolescence which currently account for ~40% of new infections. This will decrease the burden of HIV programme costs for antiretroviral drugs and antenatal care to prevent mother to child transmission.

List of abbreviations

62

95% CI 4 AE AE AL AE AL AC AL AL AC AL	615 1	List of abbreviations		
AE Adverse event AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy BCDC Centers for Disease Control and Prevention CHW Community Health Worker Case Record Form CCRF Case Record Corn Cill CK CCRF Case Polymerase Chain Reaction CCRF Ca		0E9/ CI	OF parcent Confidence Interval	
AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy CDC Centers for Disease Control and Prevention CHW Community Health Worker CRF Case Record Form CRO Contract Research Organization CT Cash transfer DfID Department for International Development, UK UK Department of Health and Social Care UK Department of Health and Social Care DMEC Data Monitoring and Ethics Committee BDSMB Data Safety Monitoring Board DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee EAC Ethics Research Committee COMMINICATION OF COMMINICATI	4		-	
ART Antiretroviral therapy CDC Centers for Disease Control and Prevention CHW Community Health Worker CRF Case Record Form CRO Contract Research Organization CT Cash transfer Cash transfer DHSC UK Department for International Development, UK Department of Health and Social Care DHSC UK Department of Health and Social Care DMEC Data Monitoring and Ethics Committee DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee ERC Ethics Research Committee CASH GCP Good Clinical Practice GEE Generalised Estimating Equation GCP GOOd Manufacturer Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HDSS Health and Demographic Surveillance System HTC HIV testing and counselling HTC HIV testing and counselling HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HUM Human immlex virus type 2 HUM Human immodeficiency virus HTD In-depth interviews HBS Institutional Review Board HTC HIV testing and counselling KEMRI Kenya Medical Research Institute HSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MMM Menstrual hygiene management MRC Medical Research Council, UK M				
CDC Centers for Disease Control and Prevention CHW Community Health Worker CRF Case Record Form CRF Case Record Form CCRO Contract Research Organization CT Cash transfer DfID Department for International Development, UK UK Department of Health and Social Care DHSC UK Department of Health and Social Care DHSC Data Monitoring and Ethics Committee BDSMB Data Safety Monitoring Board BLISA Enzyme linked immunosorbent assay ERC Ethics Research Committee ERC Ethics Research Committee CPD Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HTC HIV testing and counselling HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HIV Human simplex virus type 2 HIV Human impunodeficiency virus HRB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute Userpool School of Tropical Medicine MHM Menstrual hygiene management MIM Menstr		_		
CHW Community Health Worker CRF Case Record Form CRO Contract Research Organization CT Cash transfer DFID Department for International Development, UK DFID Department of Health and Social Care UK Department of Health and Social Care DHSC UK Department of Health and Social Care DHSC Data Monitoring and Ethics Committee DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee FDA Food and Drug Administration FOC GOOD Clinical Practice GEE Generalised Estimating Equation GOOD Focus group discussions 4 GCP GOOD Clinical Practice GEE Generalised Estimating Equation GOOD Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HTC HIV testing and counselling HSV-2 Human simplex virus type 2 III In-depth interviews IRB Institutional Review Board ITT Intention to Treat JOHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LISTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MINISTRY of Health MRC Medical Research Council, UK MRC Medical Research Council, UK PP Protocol RCC Research Ethics Committee RR Relative risk SRR Relative risk SRR Relative risk SRR Relative risk SRR Serious adverse event SAE Serious adverse event SAE Serious adverse event SAE Serious adverse event SASE Serious adverse event SAE Serious adverse avent SAE Serious adverse event SAE SAP Statistical Analysis Plan SAUAL ALISE Committee SAIP Sexually transmitted infections SWAP Safe Water and AIDS Project			• •	
CRF Case Record Form CRO Contract Research Organization CT Cash transfer DfID Department for International Development, UK DFID DEPARTMENT OF Health and Social Care DMEC Data Monitoring and Ethics Committee DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee FDA Food and Drug Administration FGD Focus group discussions GCP Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HIV Human immunodeficiency virus HIV Human immunodeficiency virus HIV Human simplex virus type 2 HIV Human simplex virus type 2 HIRB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute HIM Menstrual hygiene management MIM Menstrual hygiene management MIM Menstrual hygiene management MIM Ministry of Education, Science and Technology MIM MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per Protocol RCC Research Ethics Committee SAE Serious adverse event SAE SERIOUS SAGE SERIOUS SAGE SERIOUS SAGE SAE Serious and reproductive health SAE SERIOUS SAGE SERIOUS SAGE SAGE SERIOUS SAGE SERIOUS SAGE SAGE SERIOUS SAGE SAGE SERIOUS SAGE SAGE SERIOUS SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAG				
CRO Contract Research Organization CT Cash transfer DfID Department for International Development, UK DHSC UK Department of Health and Social Care DMEC Data Monitoring and Ethics Committee B DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee FDA Food and Drug Administration FGD Focus group discussions GEF GEF Generalised Estimating Equation GMP Good Clinical Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HTC HIV testing and counselling HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HIM In-depth interviews In Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MIM Menstrual hygiene management MIM Ministry of Health MRC Medical Research Council, UK MRC Medical Research Council, UK MGEST Ministry of Health MRC Medical Research Council, UK MGEST Randomised Controlled Trial REC Research Ethics Committee REC Research E			•	
13 CT Cash transfer 14 DfID Department for International Development, UK 15 DHSC UK Department of Health and Social Care 17 DMEC Data Monitoring and Ethics Committee 18 DSMB Data Safety Monitoring Board 19 ELISA Enzyme linked immunosorbent assay 20 ELISA Enzyme linked immunosorbent assay 21 ERC Ethics Research Committee 22 FDA Food and Drug Administration 23 FGD Focus group discussions 24 GCP Good Clinical Practice 25 GEE Generalised Estimating Equation 26 GEE Generalised Estimating Equation 27 GMP Good Manufacturer Practice 28 HDSS Health and Demographic Surveillance System 40 HIV Human immunodeficiency virus 30 HTC HIV testing and counselling 31 HTC HIV testing and counselling 32 HSV-2 Human simplex virus type 2 33 IDI In-depth interviews				
DfID Department for International Development, UK DHSC UK Department of Health and Social Care DMEC Data Monitoring and Ethics Committee BDSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay EELISA Enzyme linked imfections EELISA ENZBAR Safe Water and AIDS Project				
DHSC UK Department of Health and Social Care DMEC Data Monitoring and Ethics Committee DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee ERC Ethics Research Research Institute ERC Ethics Research Committee ERC Ethics Research Committee ERC Ethics Research Committee ERC Research Ethics Procedure ERC Research Eth		_		
DMEC Data Monitoring and Ethics Committee DSMB Data Safety Monitoring Board ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee FDA Food and Drug Administration FGD Focus group discussions GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 IBB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LSTM Liverpool School of Tropical Medicine MMM Menstrual hygiene management MOH Ministry of Education, Science and Technology MoH Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction MRC Medical Research Council, UK PCR Polymerase Chain Reaction REC Research Ethics Committee REC Research Ethics Committee REC Research Ethics Committee SAP Statistical Analysis Plan Sexually transmitted infections SAP Statistical Analysis Plan Sexually transmitted infections SAF Water and AIDS Project				
DSMB Data Safety Monitoring Board DELISA Enzyme linked immunosorbent assay EERC Ethics Research Committee FDA Food and Drug Administration FGD Focus group discussions FGD Focus group discussions FGD Good Clinical Practice FOA Good Clinical Practice FOA Good Manufacturer Practice FOA GOOD Manufacturer Practice FOA HIV Human immunodeficiency virus FOA HUM HUM HUM HUM HUM HUM HUM HOW			•	
ELISA Enzyme linked immunosorbent assay ERC Ethics Research Committee FDA Food and Drug Administration GCP Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HTC HIV testing and counselling HTC HIV testing and counselling In-depth interviews IIT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute MHM Menstrual hygiene management MHM Menstrual hygiene management MHM Menstrual hygiene management MHM Ministry of Education, Science and Technology MHM Menstrual hygiene management MHM Menstrual hygiene MHM Menstrual hygiene MHM Menstru			•	
ERC Ethics Research Committee FDA Food and Drug Administration GCP Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 IDI In-depth interviews IIT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute JSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MOH Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction MRC Medical Research Council, UK PCR Polymerase Chain Reaction REC Research Ethics Committee REC Research Ethics Committee RR Relative risk SAP Statistical Analysis Plan SEM Sexual and reproductive health SEXUALDE SEARCH SEXUALDE SEARCH SEXUALDE SEARCH SEXUALDE SEARCH SEXUALDE SEARCH FOOD SCHOOL TIPICAL MINISTRY OF Education MHC Medical Research Council, UK MEDICAL SEARCH MINISTRY OF Education MEDICAL SEARCH ME			· -	
FDA Food and Drug Administration FGD Focus group discussions FGD Focus group discussions FGD Focus group discussions FGD Focus group discussions FGE GEE Generalised Estimating Equation FGGMP Good Manufacturer Practice FIVE HIV Human immunodeficiency virus FIVE HIV Human immunodeficiency virus FIVE HIV Human simplex virus type 2 FIVE HIV HUMAN SIMPLEX HUMAN SIM	20		•	
FGD Focus group discussions GCP Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HHV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 IIT In-depth interviews IIT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MMC Medical Research Council, UK MRC Medical Research Council, UK MRC Medical Research Council, UK PCR Polymerase Chain Reaction MC Medical Research Council, UK MRC Medical Research Council Medicine MRC Medical Research Council Medicine MRC Medical Res				
GCP Good Clinical Practice GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HIR Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology Ministry of Health MRC Medical Research Council, UK MRC Medical Research Council, UK MRC Medical Research Council, UK FOR Polymerase Chain Reaction FE Protective efficacy FOR Polymerase Chain Reaction FE Protective efficacy FR RR Relative risk RRI Reproductive tract infections SAE Serious adverse event SAP Statistical Analysis Plan SEXUAL PROJECT SAP SEXUAL AIDS Project				
GEE Generalised Estimating Equation GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HIV In-depth interviews HIRB Institutional Review Board JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MHM Ministry of Health MRC Medical Research Council, UK MRC Medical Research Council, UK FOR Polymerase Chain Reaction MHM MRC Medical Research Council, UK MRC Medical Research Council, UK RES PCR Polymerase Chain Reaction REC Research Ethics Committee REC Research Ethics Committee REC Research Ethics Committee SI RR Relative risk SAE Serious adverse event SAE Sexual and reproductive health SAE Sexual and reproductive health SAE Sexual and reproductive health SAE SEXUAL AND SPROJECT			<u> </u>	
GMP Good Manufacturer Practice HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 In-depth interviews IRB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LISTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MHM Ministry of Health MRC Medical Research Council, UK RES PCR Polymerase Chain Reaction REC Research Ethics Committee RR Relative risk RR Relative risk RR Relative risk SAE Serious adverse event	25			
HDSS Health and Demographic Surveillance System HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HBB Institutional Review Board HTC HIV testing and counselling HIV testing and counselling Human simplex virus type 2 Human simplex virus type 2 HIV testing and counselling HIV testing and cou				
HIV Human immunodeficiency virus HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HBSV-2 Human simplex virus type 2 HBB Institutional Review Board HTC HIV testing and counselling HBB Institutional Review Board HBB Institutional Revi				
HTC HIV testing and counselling HSV-2 Human simplex virus type 2 HIRB Institutional Review Board JIT Intention to Treat Joint Global Health Trials KEMRI Kenya Medical Research Institute Liverpool School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MHC Medical Research Council, UK MRC Medical Research Council, UK MRC Medical Research Council of PE Protective efficacy PP Per protocol REC Research Ethics Committee RR Relative risk RR Relative risk SAE Serious adverse event SAP Statistical Analysis Plan SOP STAN Sexual and reproductive health SYAP SAFE SEXUAL SE				
HSV-2 Human simplex virus type 2 HSV-2 Human simplex virus type 2 In-depth interviews IRB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute Liverpool School of Tropical Medicine MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MMC Medical Research Council, UK MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol REC Research Ethics Committee RR Relative risk RR Relative risk SAE Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCOP Standard Operating Procedure STI Sexually transmitted infections SMAP Safe Water and AIDS Project			·	
IDI In-depth interviews IRB Institutional Review Board ITT Intention to Treat JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LIVERPOOL School of Tropical Medicine MHM Menstrual hygiene management MOEST Ministry of Education, Science and Technology MHM Menstrual hygiene Management MOEST Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial REC Research Ethics Committee RR Relative risk RR Relative risk SAE Serious adverse event SAE Serious adverse event SAE Serious adverse event SAF SCAP Statistical Analysis Plan SCAP Standard Operating Procedure STI Sexually transmitted infections SAF SERUAL SAE Serious SAF Water and AIDS Project	_		_	
34IRBInstitutional Review Board35ITTIntention to Treat36JGHTJoint Global Health Trials37JSHKEMRIKenya Medical Research Institute39LSTMLiverpool School of Tropical Medicine40MHMMenstrual hygiene management41MoESTMinistry of Education, Science and Technology43MoHMinistry of Health44MRCMedical Research Council, UK45PCRPolymerase Chain Reaction46PEProtective efficacy47PPPer protocol48PPPer protocol49RCTRandomised Controlled Trial50RECResearch Ethics Committee51RRRelative risk52RTIReproductive tract infections54SAESerious adverse event55SAPStatistical Analysis Plan56SOPStandard Operating Procedure57SRHSexual and reproductive health59STISexually transmitted infections60SWAPSafe Water and AIDS Project				
JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute Liverpool School of Tropical Medicine MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MMC Medical Research Council, UK MRC Medical Research Council, UK MEST PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol REC Research Ethics Committee RR Relative risk RR Relative risk SAE Serious adverse event SAP Statistical Analysis Plan SOP Standard Operating Procedure STI Sexually transmitted infections SWAP Safe Water and AIDS Project			•	
JGHT Joint Global Health Trials KEMRI Kenya Medical Research Institute LSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MHM Ministry of Health MRC Medical Research Council, UK MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Relative risk RR Relative risk RR Relative risk SAE Serious adverse event SAP Statistical Analysis Plan SCH SCH SEXUAL AND Project				
KEMRI Kenya Medical Research Institute Liverpool School of Tropical Medicine MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MoH Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Relative risk RR Relative risk RR Relative risk RR Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCH SCH SCH SEXUAL AND SPROLE STI SEXUAL AND SPROLE SEXUAL AND SP	36			
LSTM Liverpool School of Tropical Medicine MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MoH Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial REC Research Ethics Committee RR Relative risk RR Relative risk RR Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCH SCR Sexual and reproductive health STI Sexually transmitted infections Safe Water and AIDS Project				
MHM Menstrual hygiene management MoEST Ministry of Education, Science and Technology MoH Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Relative risk RR Relative risk RR Relative risk RR Reproductive tract infections ARE Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCP Standard Operating Procedure ST SRH Sexual and reproductive health SYLD SAE Sexually transmitted infections SWAP Safe Water and AIDS Project			•	
Moest Ministry of Education, Science and Technology Moh Ministry of Health MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Relative risk RR Relative risk RR Relative risk RR Reproductive tract infections REC Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCOP Standard Operating Procedure STOP SRH Sexual and reproductive health SEX SAF Sexual and reproductive health SEX SAF SEXUAL AND			·	
MoH Ministry of Health MRC Medical Research Council, UK MPC Medical Research Council, UK MPC PCR Polymerase Chain Reaction MPE Protective efficacy PP Per protocol MPP Per protocol MPP RCT Randomised Controlled Trial MPP REC Research Ethics Committee MPP REC RESEARCH METHOD For Italian Reproductive tract infections MPP Statistical Analysis Plan MPP Statistical Analysis Plan MPP REC RESEARCH METHOD FOR ITALIAN RESEARCH METHOD	41		, 5	
MRC Medical Research Council, UK PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Research Ethics Committee RR Relative risk RR Relative risk RR Reproductive tract infections ASE Serious adverse event ASE Serious adverse event ASE Serious adverse Procedure ASE Serious and Procedure ASE Sexual and reproductive health ASE Sexually transmitted infections ASE Sexually transmitted infections ASE Sexually Project			-	
PCR Polymerase Chain Reaction PE Protective efficacy PP Per protocol RCT Randomised Controlled Trial RR Research Ethics Committee RTI Reproductive tract infections SAE Serious adverse event SAP Statistical Analysis Plan SCO SCAP Standard Operating Procedure STO SCAP Sexual and reproductive health SCO SCAP Safe Water and AIDS Project			·	
46PEProtective efficacy4748PPPer protocol49RCTRandomised Controlled Trial50RECResearch Ethics Committee51RRRelative risk52RTIReproductive tract infections54SAESerious adverse event55SAPStatistical Analysis Plan56SOPStandard Operating Procedure57SRHSexual and reproductive health58STISexually transmitted infections60SWAPSafe Water and AIDS Project				
PP Per protocol RCT Randomised Controlled Trial REC Research Ethics Committee RES RELATION Reproductive tract infections REC Serious adverse event SER Serious adverse event SER Serious adverse Plan SER Sexual Analysis Plan SER Sexual and reproductive health SER SEXUAL RESEARCH SEXUAL R	46		•	
RCT Randomised Controlled Trial REC Research Ethics Committee RR Relative risk Reproductive tract infections REC Serious adverse event SAE Serious adverse event SAP Statistical Analysis Plan SCOP Standard Operating Procedure REC Research Ethics Committee Research Ethics Committee Reproductive tract infections SAE Serious adverse event SEC SAP Statistical Analysis Plan SEC SCOP Standard Operating Procedure REC SCOP STANDARD SECULAR S			•	
REC Research Ethics Committee RR Relative risk REC Reproductive tract infections REC Reproductive tract infections REC Reproductive tract infections REC Relative risk Reproductive tract infections REC Research Ethics Committee Relative risk Reproductive tract infections SAF Serious adverse event SEC REC RESEARCH RESEARCH RELATION SERIOUS PLANT RELATION SERIOUS PLANT RELATION SERIOUS PLANT RELATION SERIOUS PROJECT PLANT RELATION SERIOUS PLANT RELATION PLANT RELATION SERIOUS PLANT RELATION SERIOUS PLANT RELATION SERIOUS PLANT RELATION PLAN			·	
51RRRelative risk52RTIReproductive tract infections53SAESerious adverse event55SAPStatistical Analysis Plan56SOPStandard Operating Procedure57SRHSexual and reproductive health58STISexually transmitted infections60SWAPSafe Water and AIDS Project				
RTI Reproductive tract infections SAE Serious adverse event SSE SAP Statistical Analysis Plan SCOP Standard Operating Procedure STOP SEXUAL AND				
SAE Serious adverse event SAP Statistical Analysis Plan SOP Standard Operating Procedure SRH Sexual and reproductive health SRH Sexually transmitted infections SWAP Safe Water and AIDS Project				
SAP Statistical Analysis Plan SOP Standard Operating Procedure SRH Sexual and reproductive health STI Sexually transmitted infections SWAP Safe Water and AIDS Project		SAE	•	
56SOPStandard Operating Procedure57SRHSexual and reproductive health58STISexually transmitted infections60SWAPSafe Water and AIDS Project				
57 58 59 50 SRH Sexual and reproductive health Sexually transmitted infections Safe Water and AIDS Project			·	
STI Sexually transmitted infections SWAP Safe Water and AIDS Project			· -	
SWAP Safe Water and AIDS Project			•	
•			•	
	61		·	

tCTU **Tropical Clinical Trials Unit** TSC **Trial Steering Committee** WASH Water, sanitation and hygiene WHO World Health Organization

Declarations

Ethics approval and consent to participate:

This protocol, the informed parent consent and participant assent documents, and participant information sheets have been reviewed and approved by the Research Ethics Committees at the Kenya Medical Research Institute, Nairobi, Kenya (KEMRI protocol #3215) and the Liverpool School of Tropical Medicine, Liverpool (LSTM protocol #15-005). These ethics approvals cover all 96 participating Siaya schools. The Centers for Disease Control and Prevention gave approval for reliance on the KEMRI IRB (2016-136). Registry approval for trailing menstrual cups was given by the Kenyan Poisons and Pharmacy Board (ECT_16_07_06). Annual renewal of approvals by KEMRI, LSTM, and KPPB are required based on reporting of trial activities in the prior year. Written parent consents and written participant assents were collected. In the case that a parent was illiterate and could not read, verbal consent with a witnessing literate adult of the parents choosing was collected.

Consent for publication

Not applicable

Competing interests

The authors declare no conflict of interests.

Availability of Data and Materials

Not applicable: Out manuscript does not contain any data or related findings.

Funding

This study is funded by the Joint Global Health Trials Initiative (UK-Medical Research Council/Department for International Development/Wellcome Trust /Department of Health and Social Care, grant MR/N006046/1). The funders have or will have no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

Authors' contributions

PPH and FtK conceived the study. PPH, FtK, DK, DW, EZG, LM, AE, LN, AvE, and CO wrote the grant.

PPH, GZ, FtK, DK, EN, EZG, LM, AvE, CO, JJ, EK, MM, DO, BO, and GB drafted the protocol. DW and TC provided statistical guidance in the protocol, IN provided ministry and policy expertise, CH guided drafting of trial governance, and CP drafted the safety monitoring procedures. All investigators contributed to the refinement of the study protocol and approved the final version. GZ, PPH, AvE, FtK, LM, DK, TC, EZG, and DW drafted the manuscript. All authors read and approved the final manuscript prior to submission.

Acknowledgements

We are most grateful for the valuable advice and comments of the independent Trial Steering

Committee members (Robert Bailey, Sarah Baird, Marni Sommer, Sassy Molyneux, Caroline Kabiru,

Christian Borja-Vega, Jo Mulligan), and of the Data Monitoring and Ethics Committee members

(Michelle Hindin, Helen Weiss, and Jackton Omoto). We would also like to thank the LSTM

programme manager (Cheryl Giddings), research management services, and research governance

teams. Further thanks to Mooncups ® Ltd, UK, for supplying the menstrual cups at a discounted rate;

and Equity Bank, Kenya for advice and support of the cash dispersal system. Additional thanks to the

dedicated field, lab, admin, and office staff; to the Ministry of Health and Education partners,

administrative leaders, schools, and communities, and importantly to the girls and their families in

Siaya County. This paper is published with the permission of KEMRI Director. The findings and

conclusions in this paper are those of the authors and do not necessarily represent the official
 position of the Centers for Disease Control and Prevention.

References

- 1. Viner RM, Ozer EM, Denny S, Marmot M, Resnick M, Fatusi A, et al. Adolescence and the social determinants of health. Lancet. 2012;379(9826):1641-52.
- Patton GC, Coffey C, Sawyer SM, Viner RM, Haller DM, Bose K, et al. Global patterns of
 mortality in young people: a systematic analysis of population health data. Lancet.
- 673 2009;374(9693):881-92.
- Bearinger LH, Sieving RE, Ferguson J, Sharma V. Global perspectives on the sexual and
 reproductive health of adolescents: patterns, prevention, and potential. Lancet.
- 676 2007;369(9568):1220-31.
- 677 4. Chaaban J, Cunningham W. Measuring the Economic Gain of Investing in Girls The Girl
- 678 Effect Dividend. Washington, DC: World Bank; 2011. Report No.: 5753.
- 5. Doyle AM, Weiss HA, Maganja K, Kapiga S, McCormack S, Watson-Jones D, et al. The longterm impact of the MEMA kwa Vijana adolescent sexual and reproductive health intervention: effect
- of dose and time since intervention exposure. PloS one. 2011;6(9):e24866.
- 682 6. Jukes M, Simmons S, Bundy D. Education and vulnerability: the role of schools in protecting 683 young women and girls from HIV in southern Africa. Aids. 2008;22 Suppl 4:S41-56.
- 7. Biddlecom A, Gregory R, Lloyd CB, Mensch BS. Associations between premarital sex and leaving school in four sub-Saharan African countries. Stud Fam Plann. 2008;39(4):337-50.
- 8. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling

on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet.

688 2012;379(9823):1320-9.

 689 9. UN. The Sustainable Development Goals Report 2016. New York: United Nations; 2016.

- 690 10. Cluver L, Boyes M, Orkin M, Pantelic M, Molwena T, Sherr L. Child-focused state cash
- transfers and adolescent risk of HIV infection in South Africa: a propensity-score-matched case-
- 692 control study. The Lancet Global health. 2013;1(6):e362-70.
- 693 11. Handa S, Halpern CT, Pettifor A, Thirumurthy H. The government of Kenya's cash transfer
- 694 program reduces the risk of sexual debut among young people age 15-25. PloS one.
- 695 2014;9(1):e85473.
- 696 12. Cho H, Mbai I, Luseno WK, Hobbs M, Halpern C, Hallfors DD. School support as structural HIV
- 697 prevention for adolescent orphans in western Kenya. Journal of Adolescent Health. 2018;62(1):44-
- 698 51.
- 699 13. Cho H, Ryberg RC, Hwang K, Pearce LD, Iritani BJ. A School Support Intervention and
- 700 Educational Outcomes Among Orphaned Adolescents: Results of a Cluster Randomized Controlled
- 26 701 Trial in Kenya. Prevention Science. 2017;18(8):943-54.
 - 702 14. Grant M, Hallman K. Pregnancy-related school drop-out and prior school performance in
 - 703 south Africa Population Council; 2006.
 - The Hargreaues J, Morison L, Kim J, Bonell C, Porter J, al. e. The association between school
 - attendance, HIV infection and sexual behaviour among young people in rural South Africa. J
 - 706 Epidemiol Community Health. 2008;62:113-9.
 - 707 16. Juma M, Askew I, Alaii J, Bartholomew LK, van den Borne B. Cultural practices and sexual risk
 - behaviour among adolescent orphans and non-orphans: a qualitative study on perceptions from a
 - 709 community in Western Kenya. BMC public health. 2014;14:84.
 - 710 17. Oruko K, Nyothach E, Zielinski-Gutierrez E, Mason L, Alexander K, Vulule J, et al. 'He is the
 - one who is providing you with everything so whatever he says is what you do': A Qualitative Study
- 52 712 on Factors Affecting Secondary Schoolgirls' Dropout in Rural Western Kenya. PloS one.
 - 713 2015;10(12):e0144321.

- 714 18. Nobelius A-M, Kalina B, Pool R, Whitworth J, Chesters J, Power R. "You still need to give her a
- token of appreciation": the meaning of the exchange of money in the sexual relationships of out-of-
- school adolescents in rural southwest Uganda. Journal of sex research. 2010;47(5):490-503.
- 717 19. Wamoyi J, Fenwick A, Urassa M, Zaba B, Stones W. "Women's bodies are shops": Beliefs
- about transactional sex and implications for understanding gender power and HIV prevention in
- 719 Tanzania. Archives of sexual behavior. 2011;40(1):5-15.
- 14 720 20. Sommer M, Caruso BA, Sahin M, Calderon T, Cavill S, Mahon T, et al. A Time for Global
 - 721 Action: Addressing Girls' Menstrual Hygiene Management Needs in Schools. PLoS Med.
 - 722 2016;13(2):e1001962.
 - 723 21. Sommer M, Sahin M. Overcoming the taboo: advancing the global agenda for menstrual
 - hygiene management for schoolgirls. American journal of public health. 2013;103(9):1556-9.
 - 725 22. Phillips-Howard PA, Otieno G, Burmen B, Otieno F, Odongo F, Odour C, et al. Menstrual
 - 726 Needs and Associations with Sexual and Reproductive Risks in Rural Kenyan Females: A Cross-
 - 727 Sectional Behavioral Survey Linked with HIV Prevalence. J Womens Health (Larchmt).
 - 728 2015;24(10):801-11.
 - 729 23. Alexander K, Oduor C, Nyothach E, Laserson K, Amek N, Eleveld A, et al. Water, Sanitation
 - 730 and Hygiene Conditions in Kenyan Rural Schools: Are Schools Meeting the Needs of Menstruating
 - 731 Girls? Water. 2014;6:1453-66.
 - 732 24. Mason L, Nyothach E, Alexander K, Odhiambo FO, Eleveld A, Vulule J, et al. 'We keep it
 - 733 secret so no one should know' a qualitative study to explore young schoolgirls attitudes and
 - experiences with menstruation in rural Western Kenya. PloS one. 2013;8(11):e79132.
 - 735 25. Mason L, Laserson K, Oruko K, Nyothach E, Alexander K, Odhiambo F, et al. Adolescent
- 52 736 schoolgirls' experiences of menstrual cups and pads in rural western Kenya: a qualitative study.
 - 737 Waterlines. 2015;34(1):15-30.
 - 738 26. Phillips-Howard P, Nyothach E, ter Kuile F, Omoto J, Wang D, Zeh C, et al. Menstrual cups
 - and sanitary pads to reduce school attrition, and sexually transmitted and reproductive tract

- infections: a cluster randomised controlled feasibility study in rural western Kenya. BMJ Open.
- 741 2016;6:e013229.:http://dx.doi.org/10.1136/bmjopen-2016-013229.
- 742 27. Amornkul PN, Vandenhoudt H, Nasokho P, Odhiambo F, Mwaengo D, Hightower A, et al. HIV
- 743 prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya.
- 744 PloS one. 2009;4(7):e6470.
- 745 28. Buve A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L, et al. The epidemiology of
- 14 746 gonorrhoea, chlamydial infection and syphilis in four African cities. Aids. 2001;15 Suppl 4:S79-88.
 - 747 29. Baird S, Ferreira FHG, Özler B, Woolcock M. Conditional, unconditional and everything in
 - between: a systematic review of the effects of cash transfer programmes on schooling outcomes.
 - Journal of Development Effectiveness. 2015;6(1):1-43.
 - 750 30. Hallfors DD, Cho H, Rusakaniko S, Mapfumo J, Iritani B, Zhang L, et al. The impact of school
- subsidies on HIV-related outcomes among adolescent female orphans. J Adolesc Health.
 - 752 2015;56(1):79-84.
 - 753 31. Kerubo E, Laserson KF, Otecko N, Odhiambo C, Mason L, Nyothach E, et al. Prevalence of
 - 754 reproductive tract infections and the predictive value of girls' symptom-based reporting: findings
 - 755 from a cross-sectional survey in rural western Kenya. Sex Transm Infect. 2016.
 - 756 32. Juma M, Alaii J, Bartholomew LK, Askew I, Van den Borne B. Risky sexual behavior among
 - orphan and non-orphan adolescents in Nyanza Province, Western Kenya. AIDS and behavior.
 - 758 2013;17(3):951-60.
 - 759 33. Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, et al. Antibody to herpes
 - simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. The Journal of infectious
 - 761 diseases. 1999;179(1):16-24.
- 52 762 34. Luseno WK, Hallfors DD, Cho H, Iritani BJ, Adze J, Rusakaniko S, et al. Use of HIV and HSV-2
 - 563 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches. The
 - 764 journal of primary prevention. 2014;35(3):181-91.

- 765 35. Otieno FO, Ndivo R, Oswago S, Pals S, Chen R, Thomas T, et al. Correlates of prevalent
- sexually transmitted infections among participants screened for an HIV incidence cohort study in
- 767 Kisumu, Kenya. International journal of STD & AIDS. 2014.
- 768 36. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV
- acquisition: a meta-analysis of published studies. Aids. 2008;22(12):1493-501.
- 770 37. Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, et al. Bacterial vaginosis
- associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis
- 772 among African couples. PLoS Med. 2012;9(6):e1001251.
- 773 38. Mitchell C, Balkus JE, Fredricks D, Liu C, McKernan-Mullin J, Frenkel LM, et al. Interaction
- between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital
- shedding in U.S. and Kenyan women. AIDS research and human retroviruses. 2013;29(1):13-9.
- 39. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and
- 777 correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a
- 778 cross-sectional study. PloS one. 2014;9(10):e109670.
- 779 40. Jespers V, van de Wijgert J, Cools P, Verhelst R, Verstraelen H, Delany-Moretlwe S, et al. The
- 780 significance of Lactobacillus crispatus and L. vaginalis for vaginal health and the negative effect of
- 781 recent sex: a cross-sectional descriptive study across groups of African women. BMC infectious
- 782 diseases. 2015;15:115.
- 783 41. Mlisana K, Naicker N, Werner L, Roberts L, van Loggerenberg F, Baxter C, et al. Symptomatic
- vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation
- in high-risk women in South Africa. The Journal of infectious diseases. 2012;206(1):6-14.
- 786 42. Romoren M, Sundby J, Velauthapillai M, Rahman M, Klouman E, Hjortdahl P. Chlamydia and
- 787 gonorrhoea in pregnant Batswana women: time to discard the syndromic approach? BMC infectious
- 788 diseases. 2007;7:27.


- 789 43. Romoren M, Velauthapillai M, Rahman M, Sundby J, Klouman E, Hjortdahl P. Trichomoniasis
- and bacterial vaginosis in pregnancy: inadequately managed with the syndromic approach. Bulletin
- 791 of the World Health Organization. 2007;85(4):297-304.
- 792 44. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: The
- 793 KEMRI/CDC Health and Demographic Surveillance System--Western Kenya. International journal of
- 794 epidemiology. 2012;41(4):977-87.
- 14 795 45. Cohen D, Atieno-Odhiambo E. Siaya: The Historical Anthropology of an African Landscape.
 - 796 London: James Currey, Ltd; 1989.
 - 797 46. Meltzer MI, Terlouw DJ, Kolczak MS, Odhacha A, ter Kuile FO, Vulule JM, et al. The
 - household-level economics of using permethrin-treated bed nets to prevent malaria in children less
 - 799 than five years of age. Am J Trop Med Hyg. 2003;68(4):149-60.
 - 800 47. UWESO. Are Our Children Learning? Annual Learning Assessment Report 2011. Nairobi,
 - 801 Kenya: http://www.uwezo.net/publications/reports/ (accessed 1st June 2013); 2012.
 - 48. Mensch BS, Clark WH, Lloyd CB, Erulkar AS. Premarital sex, schoolgirl pregnancy, and school
 - 803 quality in rural Kenya. Stud Fam Plann. 2001;32(4):285-301.
 - 804 49. Mensch BS, Lloyd CB. Gender differences in the schooling experiences of adolescents in low-
 - income countries: the case of Kenya. Stud Fam Plann. 1998;29(2):167-84.
 - 806 50. Phillips-Howard PA, Odhiambo FO, Hamel M, Adazu K, Ackers M, van Eijk AM, et al. Mortality
 - 807 Trends from 2003 to 2009 among Adolescents and Young Adults in Rural Western Kenya Using a
 - Health and Demographic Surveillance System. PloS one. 2012;7(11):e47017.
 - 809 51. Desai M, Phillips-Howard PA, Odhiambo FO, Katana A, Ouma P, Hamel MJ, et al. An Analysis
 - of Pregnancy-Related Mortality in the KEMRI/CDC Health and Demographic Surveillance System in
- 52 811 Western Kenya. PloS one. 2013;8(7):e68733.
 - 812 52. Gargano JW, Laserson K, Muttai H, Odhiambo F, Orimba V, Adamu-Zeh M, et al. The adult
 - 813 population impact of HIV care and antiretroviral therapy in a resource poor setting, 2003-2008. Aids.
 - 814 2012;26(12):1545-54.

- 815 53. KNBS. Kenya Demographic and Health Survey 2008-09. Nairobi: Kenya National Bureau of
- 816 Statistics (KNBS) and ICF Macro; 2010.
- 817 54. Hewett PC, Mensch BS, Erulkar AS. Consistency in the reporting of sexual behaviour by
- adolescent girls in Kenya: a comparison of interviewing methods. Sex Transm Infect. 2004;80 (Suppl
- 819 2):43-8.
- 820 55. Obsidian. Menstrual Cups. https://menstrualcups.wordpress.com/ (Accessed 4 March 2017)
- 821 56. Mooncups. Advice and Facts : <u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"><u>Shift</u>"> Shift"><u>Shift</u>"> Shift"> Shi
- 822 <u>accessed 4 March 2017</u>). October 25th 2011.
- 823 57. Stewart K, Powell M, Greer R. An alternative to conventional sanitary protection: would
- women use a menstrual cup? J Obstet Gynaecol. 2009;29(1):49-52.
- 825 58. Stewart K, Greer R, Powell M. Women's experience of using the Mooncup. J Obstet
- 826 Gynaecol. 2010;30(3):285-7.
- 827 59. Oster E, Thornton R. Determinants of technology adoption: Peer effects in menstrual cup up-
- take. Journal of the European Economic Association. 2012;10(6):1263–93.
- 3 829 60. Miller T, Hallfors D, Cho H, Luseno W, Waehrer G. Cost-effectiveness of school support for
- orphan girls to prevent HIV infection in Zimbabwe. Prev Sci. 2013;14(5):503-12.
- 831 61. Alam A, Biez J, Del Carpio X. Does Cash for School Influence Young Women's Behavior in the
- 832 Longer Term? New York: The World Bank; 2011. Contract No.: 5669.
- 833 62. Galárraga O, Gertler PJ. Conditional Cash & Adolescent Risk Behaviors: Evidence from Urban
- 5 834 Mexico. Policy Research Working Paper December. 2009.
- 835 63. Attanasio O, Battistin E, Fitzsimons E, Vera-Hernandez M. How effective are conditional cash
- 836 transfers? Evidence from Colombia. 2005.
- 52 837 64. Pettifor A. Effects of cash transfer and community mobilization in young South African
 - 838 women. . 2012.
 - 839 65. Varni JW, Burwinkle TM, Seid M. The PedsQL 4.0 as a school population health measure:
 - feasibility, reliability, and validity. Qual Life Res. 2006;15(2):203-15.

- 66. NASCOP. The Kenya HIV Testing Services Guidelines. Nairobi: National AIDS and STI Control Programme (NASCOP) Ministry of Health; 2015. Report No.: ISBN - 13 978 9966 038 07 4. Blazevic D, Ederer G. Principals of biochemical tests in diagnostic microbiology. New York, NY: John Wiley and Sons; 1975. 68. Bernasconi C, Volponi G, Bonadonna L. Comparison of three different media for the detection of E. coli and coliforms in water. Water science and technology: a journal of the
- **Figure Legends**
- Figure 1: Map of Siaya County Public Health Facilities and 96 CCG Study Schools

International Association on Water Pollution Research. 2006;54(3):141-5.

- Figure 2: Flowchart of Randomization and Study Design
- **Appendices**
- Appendix 1: SPIRIT Checklist
- Appendix 2: SAE Report Form






Figure 2: Flowchart of randomisation and study design. The expected number of participants randomized to each arm and the percentage of enrolled expected to contribute to outcomes indicated (estimated FU 80% n=792).

Appendix 1 - SPIRIT Checklist

Click here to access/download
Supplementary Material
CCG SPIRIT Checklist_v8.pdf

Appendix 2 - SAE Reporting Form

Click here to access/download **Supplementary Material**Appendix 2 CCG SAE Form.pdf